<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37822557</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>What Long COVID Prevention Strategies Suggest About Its Pathophysiology.</ArticleTitle><Pagination><StartPage>ofad466</StartPage><MedlinePgn>ofad466</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofad466</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofad466</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Allan-Blitz</LastName><ForeName>Lao-Tzu</ForeName><Initials>LT</Initials><Identifier Source="ORCID">0000-0002-4077-3476</Identifier><AffiliationInfo><Affiliation>Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klausner</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><CoiStatement>Potential conflicts of interest. All authors: No reported conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>12</Day><Hour>4</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37822557</ArticleId><ArticleId IdType="pmc">PMC10563786</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofad466</ArticleId><ArticleId IdType="pii">ofad466</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bramante &#xa0;CT, Buse &#xa0;JB, Liebovitz &#xa0;DM, et al. &#xa0;Outpatient treatment of COVID-19 and incidence of post&#x2013;COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. &#xa0;Published online 8 June &#xa0;2023. doi:10.1016/S1473-3099(23)00299-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00299-2</ArticleId><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie &#xa0;Y, Choi &#xa0;T, Al-Aly &#xa0;Z. Association of treatment with nirmatrelvir and the risk of post&#x2013;COVID-19 condition. JAMA Intern Med &#xa0;2023; 183:554&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>

Uehara &#xa0;T, Yotsuyanagi &#xa0;H, Ohmagari &#xa0;N, et al.  &#xa0;Ensitrelvir for mild-to-moderate COVID-19: phase 3 part of phase 2/3 study. Available at: https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/presentation/2022/CROI20230222.pdf. Accessed 22 August 2023.</Citation></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y . Long COVID after breakthrough SARS-CoV-2 infection. Nat Med &#xa0;2022; 28(7):1461&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Emecen AN, Keskin S, Turunc O, et al . The presence of symptoms within 6 months after COVID-19: a single-center longitudinal study. Ir J Med Sci &#xa0;2023; 192(2):741&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9205653</ArticleId><ArticleId IdType="pubmed">35715663</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E, Levi R, Sarti R, et al . Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA &#xa0;2022; 328(7):676&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, et al . Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ &#xa0;2022; 377:e069676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bosworth ML, King S, et al . Risk of long COVID in people infected with severe acute respiratory syndrome coronavirus 2 after 2 doses of a coronavirus disease 2019 vaccine: community-based, matched cohort study. Open Forum Infect Dis &#xa0;2022; 9(9):ofac464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9494414</ArticleId><ArticleId IdType="pubmed">36168555</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, et al . Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis &#xa0;2022; 22(1):43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon MA, Luginbuhl RD, Parker R . Reduced incidence of long-COVID symptoms related to administration of COVID-19 vaccines both before COVID-19 diagnosis and up to 12 weeks after. medRxiv &#xa0;2021:2021.11.17.21263608. 10.1101/2021.11.17.21263608</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.17.21263608</ArticleId></ArticleIdList></Reference><Reference><Citation>Senjam SS, Balhara YPS, Kumar P, et al . Assessment of post COVID-19 health problems and its determinants in North India: a descriptive cross section study. medRxiv &#xa0;2021:2021.10.03.21264490. 10.1101/2021.10.03.21264490</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.03.21264490</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe &#xa0;A, Iwagami &#xa0;M, Yasuhara &#xa0;J, Takagi &#xa0;H, Kuno &#xa0;T. Protective effect of COVID-19 vaccination against long COVID syndrome: a systematic review and meta-analysis. Vaccine &#xa0;2023; 41:1783&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank &#xa0;Z, Senussi &#xa0;Y, Manickas-Hill &#xa0;Z, et al. &#xa0;Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis &#xa0;2023; 76:e487&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim &#xa0;S, Lowe &#xa0;JR, Bramante &#xa0;CT, et al. &#xa0;Metformin and COVID-19: focused review of mechanisms and current literature suggesting benefit. Front Endocrinol (Lausanne) &#xa0;2021; 12:587801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342037</ArticleId><ArticleId IdType="pubmed">34367059</ArticleId></ArticleIdList></Reference><Reference><Citation>Parthasarathy &#xa0;H, Tandel &#xa0;D, Siddiqui &#xa0;AH, Harshan &#xa0;KH. Metformin suppresses SARS-CoV-2 in cell culture. Virus Res &#xa0;2022; 323:199010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9676078</ArticleId><ArticleId IdType="pubmed">36417940</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller &#xa0;MA, Sharma &#xa0;Y, Dupee &#xa0;Z, et al. &#xa0;Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses. JCI Insight &#xa0;2021; 6:e148003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8492301</ArticleId><ArticleId IdType="pubmed">34357881</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun &#xa0;X, Liu &#xa0;Y, Huang &#xa0;Z, et al. &#xa0;SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1. Cell Death Differ &#xa0;2022; 29:1240&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9177730</ArticleId><ArticleId IdType="pubmed">34997207</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnik &#xa0;R, Lopez Mingorance &#xa0;F, Rivera &#xa0;F, Mitchell &#xa0;F, Gonzalez &#xa0;CD, Vaccaro &#xa0;MI. Autophagy in inflammatory response against SARS-CoV-2. Int J Mol Sci &#xa0;2023; 24:4928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10002778</ArticleId><ArticleId IdType="pubmed">36902354</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellors &#xa0;JW, Munoz &#xa0;A, Giorgi &#xa0;JV, et al. &#xa0;Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med &#xa0;1997; 126:946&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">9182471</ArticleId></ArticleIdList></Reference><Reference><Citation>Ananworanich &#xa0;J, Chomont &#xa0;N, Eller &#xa0;LA, et al. &#xa0;HIV DNA set point is rapidly established in acute HIV infection and dramatically reduced by early ART. EBioMedicine &#xa0;2016; 11:68&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5049918</ArticleId><ArticleId IdType="pubmed">27460436</ArticleId></ArticleIdList></Reference><Reference><Citation>Yotsuyanagi &#xa0;H, Ohmagari &#xa0;N, Doi &#xa0;Y, et al. &#xa0;Efficacy and safety of 5-day oral ensitrelvir for patients with mild-to-moderate COVID-19: the SCORPIO-SR Randomized Clinical Trial. medRxiv. Preprint posted online July 13, 2023. doi:10.1101/2023.07.11.23292264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.07.11.23292264</ArticleId><ArticleId IdType="pmc">PMC10858401</ArticleId><ArticleId IdType="pubmed">38335000</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond &#xa0;J, Leister-Tebbe &#xa0;H, Gardner &#xa0;A, et al. &#xa0;Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med &#xa0;2022; 386:1397&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>